具有细胞因子中和能力的嵌合抗原受体T细胞
该研究设计了一种非信号型膜结合IL-6受体(mbaIL6),与抗CD19-41BB-CD3ζ CAR共表达于T细胞,体外可快速清除培养上清中的IL-6并中和其信号与功能,且不影响CAR-T细胞的体外细胞毒性和增殖;在异种移植模型中,共表达mbaIL6的CAR-T细胞抗肿瘤有效,同时小鼠体内人IL-6水平大幅降低。
要点
- mbaIL6由抗IL-6抗体来源的单链可变片段与跨膜锚定肽构成,表达于T细胞表面。
- mbaIL6+ T细胞可快速清除培养上清中的IL-6,清除量与mbaIL6+细胞数量成比例。
- 共表达mbaIL6与CAR的T细胞体外细胞毒性和增殖与单表达CAR的细胞相同。
核心结论
- 携带IL-6清除能力的CAR-T细胞是预防细胞因子释放综合征并降低其严重程度、同时不影响CAR-T细胞抗肿瘤潜力的新方法。
研究设计与样本
- 研究设计为构建非信号型膜结合IL-6受体(mbaIL6)并与抗CD19-41BB-CD3ζ CAR共表达于T细胞,进行体外功能检测和异种移植模型实验。
主要发现
- mbaIL6表达于T细胞表面可快速清除培养上清中的IL-6,清除量与mbaIL6+细胞数量成比例,并随T细胞增殖而增加。
- mbaIL6可中和IL-6信号与功能。
- 共表达mbaIL6和CAR的T细胞体外细胞毒性和增殖与单表达CAR的细胞相同。
- 在异种移植模型中,无论是否表达mbaIL6,CAR-T细胞均有效。
- 小鼠体内人IL-6水平在T细胞共表达两种受体而非单表达CAR时大幅降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Infusion of T lymphocytes expressing chimeric antigen receptors (CARs) can produce extraordinary antitumor activity in patients with leukemia, lymphoma, and myeloma. The signaling mechanisms activating T cells and provoking tumor cell killing also trigger cytokine secretion and macrophage activation, leading to cytokine release syndrome (CRS). CRS is a serious side effect of CAR-T cells, and proinflammatory interleukin-6 (IL-6) is central to its pathogenesis. To endow T cells with anti-CRS activity, we designed a nonsignaling membrane-bound IL-6 receptor (mbaIL6) constituted by a single chain variable fragment derived from an anti-IL-6 antibody linked to a transmembrane anchoring peptide. We found that mbaIL6 expressed on the surface of T cells could rapidly remove IL-6 from the culture supernatant. IL-6 removal was proportional to the number of mbaIL6+ cells, increased with T-cell proliferation, and neutralized IL-6 signaling and function. A construct encoding for mbaIL6 and an anti-CD19-41BB-CD3ζ CAR allowed simultaneous expression of both receptors. T cells with mbaIL6 and CAR neutralized macrophage-derived IL-6 while exerting powerful antitumor activity. Cytotoxicity and proliferation were identical to those of cells expressing CAR alone in vitro, and CAR-T cells were effective in xenograft models regardless of mbaIL6 expression. Levels of human IL-6 in mice, however, were greatly reduced if T cells expressed both receptors instead of CAR alone. Thus, CAR-T cells with on-board capacity to extinguish IL-6 represent a new approach to prevent CRS and suppress its severity without affecting the antitumor potential of CAR-T cells.
引用
- Tan AHJ, Vinanica N, Campana D, et al. Chimeric antigen receptor-T cells with cytokine neutralizing capacity. Blood Adv. 2020. PMID: 32271901. doi:10.1182/bloodadvances.2019001287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。